Long-term Immunogenicity of the 13-valent Pneumococcal Conjugate Vaccine during Adjuvant Chemotherapy in Patients with Gastric and Colorectal Cancer: A 5-Year Follow-up of a Randomized Controlled Trial
Vaccination timing is not a significant factor for the immunogenicity of PCV13 in cancer patients undergoing adjuvant chemotherapy. Global protection against pneumococcal infection was sustained for > 5 years, and global response remained in over half of patients.
Authors
- Hyun-Jin Bang
- Hyeon-Jong Kim (ORCID: https://orcid.org/0000-0003-2722-6520)
- Seung‐Ji Kang (ORCID: https://orcid.org/0000-0002-3298-0520)
- A-Yeung Jang (ORCID: https://orcid.org/0000-0002-4050-2107)
- Seung‐Hoon Beom (ORCID: https://orcid.org/0000-0001-7036-3753)
- Woo Kyun Bae (ORCID: https://orcid.org/0000-0003-0267-1943)
- Jun‐Eul Hwang (ORCID: https://orcid.org/0000-0002-3768-4149)
- Jong Gwang Kim (ORCID: https://orcid.org/0000-0002-7615-5864)
- Joon Young Song (ORCID: https://orcid.org/0000-0002-0148-7194)
- Sang‐Hee Cho (ORCID: https://orcid.org/0000-0002-7995-7862)
- Hyun-Jung Shim
- Ik‐Joo Chung (ORCID: https://orcid.org/0000-0002-4400-7779)
Institutions
- International Vaccine Institute (KR)
- Yonsei University (KR)
- Korea University (KR)
- Kyungpook National University (KR)
- Chonnam National University Hwasun Hospital (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-02-12
- DOI
- https://doi.org/10.4143/crt.2024.1083
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- Ministry of Science and ICT, South Korea